Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691908 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL19692314 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1476715 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1476747 | 1.00 | ALOX5 (0.55) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2961154 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL2966938 | 0.94 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18657390 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL29971764 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL18685663 | 0.88 | ALOX5 (0.65) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL9376923 | 0.87 | ALOX5 (0.43) | ALOX5ALDH1A1EPHX1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117128-A1 | INTRAOCULAR PRESSURE LOWERING AGENT, AND AGENT FOR TREATING OR PREVENTING GLAUCOMA OR OCULAR HYPERTENSION | ＳＡＮＳＨＯ株式会社 | 2024-06-06 | — | — | WO | disclosed |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | SANSHO CO. LTD. (JP) | 2024-04-11 | — | — | US | disclosed |
| EP-4252756-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | Sansho Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| CN-116710105-A | Therapeutic agent for pulmonary fibrosis | 山椒株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | OCHANOMIZU UNIVERSITY (JP) | 2023-04-06 | — | — | US | disclosed |
| US-10413559-B2 | Method for treating demyelinating disease | OCHANOMIZU UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-2949329-B1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | UNIV OCHANOMIZU (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2803359-B1 | THERAPEUTIC AGENT FOR JOINT DISEASES | SANSHO CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | OCHANOMIZU UNIVERSITY (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2949329-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | Ochanomizu University (JP) | 2015-12-02 | — | — | EP | disclosed |
| EP-1402894-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVES | MUROFUSHI KIMIKO (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070161604-A1 | Highly active lysophosphatidic acid and method of screening therewith | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20060122155-A1 | Carbacyclic phosphatidic acid derivative | SANSHO CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1535926-A1 | CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVE | Murofushi, Kimiko (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040220149-A1 | Nerve cell survival promoters containing cyclic phosphatidic acid derivative | GENCOM CORPORATION (JP) | 2004-11-04 | — | — | US | disclosed |
| US-20040214799-A1 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives | MUROFUSHI, KIMIKO (JP) | 2004-10-28 | — | — | US | disclosed |
| US-20040176329-A1 | Drugs for promoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid | KIMIKO MUROFUSHI (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1402894-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING CARBACYCLIC PHOSPHATIDIC ACID DERIVATIVES | Gencom Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1391204-A1 | NERVE CELL SURVIVAL PROMOTERS CONTAINING CYCLIC PHOSPHATIDIC ACID DERIVATIVE | Gencom Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1386612-A1 | DRUGS FO RPROMOTING THE PROLIFERATION, DIFFERENTIATION AND/OR SURVIVAL OF GLIAL CELLS CONTAINING CYCLIC PHOSPHATIDIC ACID | Gencom Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108750-A1 | CARBALYSOPHOSPHATIDIC ACID | PHOSPHO1, SGMS1, PLD1 | ALOX5 408/4885ALDH1A1 3690/4885EPHX1 756/4885 |
| US-20040214799-A1 | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives | PTEN, PLCB1, PLCG2 | ALOX5 387/4885ALDH1A1 2283/4885EPHX1 783/4885 |
| US-20040176329-A1 | Drugs for promoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid | GAP43, SMPD2, SMPD3 | ALOX5 596/4885ALDH1A1 3248/4885EPHX1 488/4885 |
| US-20150352132-A1 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE | PMP22, MAG, SGMS1 | ALOX5 399/4885ALDH1A1 3983/4885EPHX1 1090/4885 |
| US-20060122155-A1 | Carbacyclic phosphatidic acid derivative | SGMS1, SGMS2, LPAR2 | ALOX5 336/4885ALDH1A1 3742/4885EPHX1 1948/4885 |
| US-10413559-B2 | Method for treating demyelinating disease | PMP22, MAG, SGMS1 | ALOX5 210/4885ALDH1A1 3689/4885EPHX1 797/4885 |
| US-20070161604-A1 | Highly active lysophosphatidic acid and method of screening therewith | LPAR2, LPAR1, LPAR6 | ALOX5 71/4885ALDH1A1 1041/4885EPHX1 226/4885 |
| US-20240115586-A1 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS | CCL11, ELANE, MMP1 | ALOX5 384/4885ALDH1A1 626/4885EPHX1 1567/4885 |
| US-20040220149-A1 | Nerve cell survival promoters containing cyclic phosphatidic acid derivative | NGF, GAP43, PLA2G4A | ALOX5 842/4885ALDH1A1 3386/4885EPHX1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.